{
  "id": 1476,
  "text": "Pooled survival rates published by Lukka et al.1456 from six RCTs1383,1397,1413,1416,1418,1420 that evaluated the role of cisplatin, alone or in combination with other chemotherapy agents, administered concurrently with EBRT, showed a statistically significant effect in favour of cisplatin-based chemoradiotherapy compared with radiotherapy without cisplatin $\\mathrm { { R R = 0 .",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: Pooled survival rates published by Lukka et al.1456 from six RCTs1383,1397,1413,1416,1418,1420 that evaluated the role of cisplatin, alone or in combination with other chemotherapy agents, administered concurrently with EBRT, showed a statistically significant effect in favour of cisplatin-based chemoradiotherapy compared with radiotherapy without cisplatin $\\mathrm { { R R = 0 .\n\n<question>: ",
  "ChatGPT_response_0": "在实际临床应用中，顺铂化疗结合放疗的优势体现在多个方面。首先，顺铂作为一种重要的化疗药物，可以增强放疗的治疗效果，提高肿瘤的灭活率。其次，顺铂化疗结合放疗可以通过不同的途径影响肿瘤细胞的代谢活动，从而产生协同作用，达到更好的治疗效果。此外，顺铂还具有较广泛的抗肿瘤谱，可以覆盖多种癌症类型，适用范围广泛。最后，顺铂化疗结合放疗可以减少肿瘤细胞的耐药性，延长患者的生存时间，并且可以减少肿瘤复发的可能性。综合来看，顺铂化疗结合放疗在临床应用中表现出显著的优势效果。",
  "query": "在Lukka等人发表的涉及顺铂和其他化疗药物联合放疗的六个随机对照试验中，顺铂化疗与放疗相比表现出显著优势效果。在实际临床应用中，你认为顺铂化疗结合放疗的优势体现在哪些方面？",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 在Lukka等人发表的涉及顺铂和其他化疗药物联合放疗的六个随机对照试验中，顺铂化疗与放疗相比表现出显著优势效果。在实际临床应用中，你认为顺铂化疗结合放疗的优势体现在哪些方面？\n\n<reference text>: Pooled survival rates published by Lukka et al.1456 from six RCTs1383,1397,1413,1416,1418,1420 that evaluated the role of cisplatin, alone or in combination with other chemotherapy agents, administered concurrently with EBRT, showed a statistically significant effect in favour of cisplatin-based chemoradiotherapy compared with radiotherapy without cisplatin $\\mathrm { { R R = 0 .\n\n<reply>: ",
  "response": "在实际临床应用中，顺铂化疗结合放疗的优势体现在多个方面。首先，顺铂作为一种重要的化疗药物，可以增强放疗的治疗效果，提高肿瘤的灭活率。其次，顺铂化疗结合放疗可以通过不同的途径影响肿瘤细胞的代谢活动，从而产生协同作用，达到更好的治疗效果。此外，顺铂还具有较广泛的抗肿瘤谱，可以覆盖多种癌症类型，适用范围广泛。最后，顺铂化疗结合放疗可以减少肿瘤细胞的耐药性，延长患者的生存时间，并且可以减少肿瘤复发的可能性。综合来看，顺铂化疗结合放疗在临床应用中表现出显著的优势效果。"
}